Cita APA

Goddard, J., Castle, J., Southworth, E., Fletcher, A., Crosier, S., Martín Guerrero, I., . . . Hicks, D. (2023). Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.

Citación estilo Chicago

Goddard, Jack, et al. Molecular Characterisation Defines Clinically-actionable Heterogeneity Within Group 4 Medulloblastoma and Improves Disease Risk-stratification. 2023.

Cita MLA

Goddard, Jack, et al. Molecular Characterisation Defines Clinically-actionable Heterogeneity Within Group 4 Medulloblastoma and Improves Disease Risk-stratification. 2023.